Ashton Thomas Private Wealth’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Ashton Thomas Private Wealth’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$30.4K	Buy	+373	New	+$30.9K	﹤0.01%	1319
2024 Q3	–	Sell	-129	Closed	-$7.64K	–	749
2024 Q2	$7.64K	Buy	+129	New	+$7.14K	﹤0.01%	1415

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

KFS

Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CAG

Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Ashton Thomas Private Wealth's BIB Position: Q1 2026 in Review

Ashton Thomas Private Wealth opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 373 shares worth $30.4K. The stake represents ﹤0.01% of the portfolio and ranks #1319 among its holdings. This is a return to the name: Ashton Thomas Private Wealth previously reported a position in BIB as recently as Q2 2024.

Ashton Thomas Private Wealth first reported a position in BIB in Q2 2024 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

Ashton Thomas Private Wealth held 373 shares of ProShares Ultra NASDAQ Biotechnology worth $30.4K as of Q1 2026.
ProShares Ultra NASDAQ Biotechnology was a new Ashton Thomas Private Wealth position in Q1 2026.
ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #1319 holding.
Ashton Thomas Private Wealth first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2024 and has held it in 2 quarters since.
23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.